Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor

Simple Summary Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative option for high-risk hematologic malignancies. However, disease recurrence after allo-HSCT remains a critical issue, underlining the need to develop maintenance therapy. In this context, NK cell-based immunotherapies could enhance graft-versus-tumor effect without triggering graft-versus-host disease. In this prospective phase I clinical trial, we demonstrated the safety of donor-derived NK cell infusion as a prophylactic treatment after allo-HSCT for patients with hematological malignancies. This opens perspectives for future developments of NK cell based therapeutic strategies after allo-HSCT with low incidence of GVHD, representing an advantage over post-transplant T cell modulations that are commonly used in clinical routine. Abstract Background: NK cell-based immunotherapy to prevent relapse after allogeneic transplantation is an appealing strategy because NK cells can provide strong antitumor effect without inducing graft-versus-host disease (GVHD). Thus, we designed a phase-I clinical trial evaluating the safety of a prophylactic donor-derived ex vivo IL-2 activated NK cell (IL-2 NK) infusion after allo-HSCT for patients with hematologic malignancies. Methods: Donor NK cells were purified and cultured ex vivo with IL-2 before infusion, at three dose levels. To identify the maximum tolerated dose was the main objective. In addition, we performed phenotypical and functional characterization of the NK cell therapy product, and longitudinal immune monitoring of NK cell phenotype in patients. Results: Compared to unstimulated NK cells, IL-2 NK cells expressed higher levels of activating receptors and exhibited increased degranulation and cytokine production in vitro. We treated 16 patients without observing any dose-limiting toxicity. At the last follow up, 11 out of 16 treated patients were alive in complete remission of hematologic malignancies without GVHD features and immunosuppressive treatment. Conclusions: Prophylactic donor-derived IL-2 NK cells after allo-HSCT is safe with low incidence of GVHD. Promising survivals and IL-2 NK cell activated phenotype may support a potential clinical efficacy of this strategy.

[1]  P. Thall,et al.  Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. , 2020, The New England journal of medicine.

[2]  Clara Di Vito,et al.  Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies , 2019, Front. Immunol..

[3]  T. Nakamaki,et al.  Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia , 2019, International journal of molecular sciences.

[4]  U. Germing,et al.  Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment , 2019, International journal of molecular sciences.

[5]  D. Blaise,et al.  Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3+ cells , 2018, British journal of haematology.

[6]  O. Lantz,et al.  Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells , 2018, Cell.

[7]  É. Vivier,et al.  Natural killer cells and other innate lymphoid cells in cancer , 2018, Nature Reviews Immunology.

[8]  J. Esteve,et al.  Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation , 2018, Bone Marrow Transplantation.

[9]  J. Wagner,et al.  Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  É. Vivier,et al.  Activating and inhibitory receptors expressed on innate lymphoid cells , 2018, Seminars in Immunopathology.

[11]  S. Bicciato,et al.  The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation , 2018, Haematologica.

[12]  Depei Wu,et al.  IL‐12/IL‐18‐preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation , 2018, European journal of immunology.

[13]  M. Davids,et al.  Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. , 2018, Blood.

[14]  P. Parham,et al.  Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. , 2018, Blood.

[15]  G. Oliveira,et al.  NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. , 2018, Blood.

[16]  K. Rezvani,et al.  Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. , 2017, Blood.

[17]  A. Cerwenka,et al.  Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation , 2017, Front. Immunol..

[18]  R. Negrin,et al.  Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation , 2017, Front. Immunol..

[19]  D. Blaise,et al.  Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML , 2017, Bone Marrow Transplantation.

[20]  J. Esteve,et al.  Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT , 2016, Bone Marrow Transplantation.

[21]  F. Claas,et al.  Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia , 2016, Science Translational Medicine.

[22]  L. Castagna,et al.  Donor lymphocyte infusion after allogeneic stem cell transplantation. , 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[23]  H. Kolb,et al.  Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation , 2016, Bone Marrow Transplantation.

[24]  A. Tosti,et al.  Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells , 2016, Haematologica.

[25]  A. Schwarer,et al.  NK cell maturation to CD56(dim) subset associated with high levels of NCRs overrides the inhibitory effect of NKG2A and recovers impaired NK cell cytolytic potential after allogeneic hematopoietic stem cell transplantation. , 2016, Leukemia research.

[26]  H. Putter,et al.  Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion , 2016, Haematologica.

[27]  A. Cerwenka,et al.  Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy , 2015, Cytotherapy.

[28]  S. Granjeaud,et al.  Reconstitution of natural killer cells in HLA-matched HSCT after reduced-intensity conditioning: impact on clinical outcome. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  P. Chevallier,et al.  Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial , 2015, Haematologica.

[30]  J. Scarisbrick,et al.  A multicentre UK study of GVHD following DLI: Rates of GVHD are high but mortality from GVHD is infrequent , 2015, Bone Marrow Transplantation.

[31]  R. Bouabdallah,et al.  Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  H. Vié,et al.  ADAM17-Mediated Shedding of FcγRIIIA on Human NK Cells: Identification of the Cleavage Site and Relationship with Activation , 2014, The Journal of Immunology.

[33]  Bin Zhang,et al.  NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). , 2013, Blood.

[34]  Bin Zhang,et al.  NK cell CD 16 surface expression and function is regulated by a disintegrin and metalloprotease-17 ( ADAM 17 ) , 2013 .

[35]  Elaine Coustan-Smith,et al.  Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. , 2012, Cytotherapy.

[36]  Eric Vivier,et al.  Targeting natural killer cells and natural killer T cells in cancer , 2012, Nature Reviews Immunology.

[37]  Y. Kerdiles,et al.  Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor , 2011, Proceedings of the National Academy of Sciences.

[38]  Baptiste N. Jaeger,et al.  Confinement of Activating Receptors at the Plasma Membrane Controls Natural Killer Cell Tolerance , 2011, Science Signaling.

[39]  R. Negrin,et al.  NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. , 2010, Blood.

[40]  É. Vivier,et al.  Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo , 2009, Proceedings of the National Academy of Sciences.

[41]  M. Berg,et al.  Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. , 2009, Cytotherapy.

[42]  D. Campana,et al.  Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. , 2009, Cancer research.

[43]  J. Schold,et al.  The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease , 2008, Haematologica.

[44]  Eric Vivier,et al.  Functions of natural killer cells , 2008, Nature Immunology.

[45]  M. Labopin,et al.  Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Marcela R. Uribe,et al.  Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia , 2007, Leukemia.

[47]  G. Ledderose,et al.  Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[49]  G. Gastl,et al.  Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells. , 2003, Immunobiology.

[50]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[51]  L. Moretta,et al.  NKp44, a Novel Triggering Surface Molecule Specifically Expressed by Activated Natural Killer Cells, Is Involved in Non–Major Histocompatibility Complex–restricted Tumor Cell Lysis , 1998, The Journal of experimental medicine.

[52]  S. Sforzini,et al.  The natural killer-related receptor for HLA-C expressed on T cells from CD3+ lymphoproliferative disease of granular lymphocytes displays either inhibitory or stimulatory function. , 1996, Blood.

[53]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.